# Cytosorbents (CTSO) — Earnings

CTSO · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/ctso/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$20.00 |
| EPS estimate | −$1.40 |
| EPS surprise | −1328.57% |
| Revenue surprise | +0.34% |
| Revenue | $9.6M |
| Revenue estimate | $9.6M |
| Reported | Aug 6, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1175151/000110465926092006/ctso-20260630x10q.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/98ea0438-4775-d1a3-6531-ddfa8f87b2fd.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 6, 2026 | −$1.40 | −$20.00 | -1328.57% | $9.6M | $9.6M |
| Q1 2026 | May 13, 2026 | −$1.00 | −$20.00 | -1900.00% | $9.4M | $8.9M |
| Q4 2025 | Mar 25, 2026 | −$1.10 | −$36.00 | -3172.73% | $9.8M | $9.2M |
| Q3 2025 | Nov 13, 2025 | −$0.80 | −$0.80 | 0.00% | $10.4M | $9.5M |
| Q2 2025 | Aug 7, 2025 | −$1.00 | $0.60 | 160.00% | $9.4M | $9.6M |
| Q1 2025 | May 14, 2025 | −$1.30 | −$0.40 | 69.23% | $9.2M | $8.7M |
| Q4 2024 | Mar 31, 2025 | −$1.00 | −$2.80 | -180.00% | $10.2M | $9.2M |
| Q3 2024 | Nov 7, 2024 | −$1.10 | −$0.80 | 27.27% | $10.4M | $9.4M |
| Q2 2024 | Aug 13, 2024 | −$1.95 | −$1.60 | 17.95% | $9.7M | $9.9M |
| Q1 2024 | May 9, 2024 | −$2.40 | −$2.40 | 0.00% | $9.8M | $9.8M |
| Q4 2023 | Mar 15, 2024 | −$2.75 | −$2.40 | 12.73% | $9.3M | $8.7M |
| Q3 2023 | Nov 9, 2023 | −$2.47 | −$4.20 | -70.27% | $9.5M | $8.8M |
| Q2 2023 | Aug 1, 2023 | −$2.26 | −$2.80 | -23.69% | $11.0M | $9.4M |
| Q1 2023 | May 2, 2023 | −$2.53 | −$3.40 | -34.21% | $8.7M | $9.4M |
| Q4 2022 | Mar 9, 2023 | −$3.50 | −$0.20 | 94.29% | $8.5M | $9.4M |
| Q3 2022 | Nov 3, 2022 | −$3.30 | −$5.60 | -69.70% | $9.0M | $8.1M |
| Q2 2022 | Aug 2, 2022 | −$2.67 | −$5.00 | -86.96% | $9.6M | $8.5M |
| Q1 2022 | May 3, 2022 | −$2.88 | −$4.20 | -45.83% | $9.7M | $8.7M |
| Q4 2021 | Mar 8, 2022 | −$2.51 | −$4.20 | -67.54% | $9.7M | $10.8M |
| Q3 2021 | Nov 4, 2021 | −$2.43 | −$3.00 | -23.42% | $9.7M | $9.8M |

## Frequently Asked Questions

### When did Cytosorbents (CTSO) last report earnings?

Cytosorbents last reported on Aug 6, 2026, covering fiscal Q2 2026.

### Did CTSO beat earnings estimates?

No. Cytosorbents reported EPS of −$20.00 for Q2 2026 against a −$1.40 estimate — a 1328.57% miss.

### How much revenue did CTSO report last quarter?

Cytosorbents reported $9.6M in revenue for Q2 2026, against a consensus estimate of $9.6M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).